Guidelines for tuberculosis prophylaxis during anti-tumour necrosis factor-α treatment: Indian rheumatology association

APLAR Journal of Rheumatology

Volumn 9, Issue 2, 2006, Pages 181-183

  Handa, Rohini ^a   Misra, R ^b   Chaturvedi, V P ^c   Pispati, P K ^d   Rao, U R K ^e   Joshi, V R ^f  

^a ALL INDIA INSTITUTE OF MEDICAL SCIENCES   (India)

^b SANJAY GANDHI POSTGRADUATE INSTITUTE OF MEDICAL SCIENCES   (India)

^c ARMY HOSPITAL RESEARCH AND REFERRAL   (India)

^d JASLOK HOSPITAL AND RESEARCH CENTRE   (India)

^e Sri Deepti Rheumatology Centre   (India)

^f P D HINDUJA NATIONAL HOSPITAL   (India)

Author keywords

Guidelines; Rheumatoid arthritis; Tuberculosis

Indexed keywords

BCG VACCINE; CORTICOSTEROID; DISEASE MODIFYING ANTIRHEUMATIC DRUG; IMMUNOSUPPRESSIVE AGENT; INFLIXIMAB; ISONIAZID; METHOTREXATE; PYRIDOXINE; RIFAMPICIN; TUBERCULOSTATIC AGENT; TUMOR NECROSIS FACTOR ALPHA INHIBITOR;

ANOREXIA; ANTIBIOTIC RESISTANCE; ARTICLE; BACTERIUM CULTURE; CLINICAL TRIAL; CONSENSUS DEVELOPMENT; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; DRUG TREATMENT FAILURE; DRUG WITHDRAWAL; EXTRAPULMONARY TUBERCULOSIS; FEVER; HUMAN; INDIA; INFECTION PREVENTION; INFECTION RISK; LUNG TUBERCULOSIS; MEDICAL EXPERT; MEDICAL SOCIETY; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; RHEUMATOLOGY; RISK REDUCTION; SIDE EFFECT; THORAX RADIOGRAPHY; TUBERCULIN TEST; WEIGHT REDUCTION;

EID: 33745935560     PISSN: 02190494     EISSN: 14798077     Source Type: Journal    
DOI: 10.1111/j.1479-8077.2006.00181.x     Document Type: Article

References (20)

1. Malaviya AN, Kapoor SK, Singh RR, Kumar A, Pande I (1993) Prevalence of rheumatoid arthritis in the adult Indian population. Rheumatol Int 13, 131-4.
2. Revised National Tuberculosis Control Programme. (2005) Technical Guidelines for Tuberculosis Control. Central TB Division, Directorate General of Health Services, New Delhi. Available at: http://www.tbcindia.org/pdfs/TECHGUIDE-2000.pdf. Accessed 26 October 2005.
3. Grover R, Kapoor S, Marwaha V, Chaturvedi V, Gupta R, Kumar A (2005) Clinical experience with infliximab in spondyloarthropathy: An open label study in fourteen patients. J Ind Rheumatol Assoc 13, 78-82.
4. Misra R, Amin S, Joshi VR, et al. (2005) Open label evaluation of the efficacy and safety of etanercept in rheumatoid arthritis. J Ind Rheumatol Assoc 13, 131-4.
5. Wang L, Turner M, Elwood R, Schulzer M, Fitzgerald JM (2002) A meta-analysis of the effect of Bacille Calmette Guerin vaccination on tuberculin skin test measurements. Thorax: 57, 804-9. Erratum in: Thorax 2003 58: 188.
6. Ledingham J, Wilkinson C, Deighton C (2005) British Thoracic Society Recommendations for assessing risk and managing Tuberculosis in patients due to start Anti-TNF-α treatments. Rheumatology 44, 1205-6.
7. British Thoracic Society Standards of Care Committee. (2005) BTS recommendations for assessing risk and managing Mycobacterium tuberculosis infection and disease in patients due to start Anti-TNF-α treatment. Thorax 60, 800-5.
8. Ponce de Leon D, Acevedo-Vasquez E, Sanchez-Torres A, et al. (2005) Attenuated response to purified protein derivative in patients with rheumatoid arthritis: Study in a population with a high prevalence of tuberculosis. Ann Rheum Dis 64, 1360-1.
9. Lodha R, Kabra SK (2004) Newer diagnostic modalities for tuberculosis. Indian J Pediatr 71, 221-7.
10. Mazurek GH, Jereb J, Lobue P, Iademarco MF, Metchock B, Vernon A (2005) Division of Tuberculosis Elimination, National Center for HIV, STD, and TB Prevention, Centers for Disease Control and Prevention (CDC). MMWR Recomm Rep 54, 49-55.
11. Winthrop KL, Siegel JN, Jereb J, Taylor Z, Iademarco MF (2005) Tuberculosis associated with therapy against Tumor Necrosis Factor α. Arthritis Rheum 52, 2968-74.
12. American Thoracic Society. (2000) Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med 161, S221-47.
13. CDC. (2003) Update: Adverse event data and revised American Thoracic Society/CDC recommendations against the use of rifampin and pyrazinamide for treatment of latent tuberculosis infection: United States, 2003. MMWR Morb Mortal Wkly Rep 52, 735-9.
14. Myers JP (2005) New recommendations for the treatment of tuberculosis. Curr Opin Infect Dis 18, 133-40.
15. Gardam MA, Keystone EC, Menzies R, et al. (2003) Anti tumour necrosis factor agents and tuberculosis risk. Mechanisms of action and clinical management. Lancet Infect Dis 3, 148-55.
16. Gaitonde S, Pathan E, Sule A, Mittal G, Joshi VR (2002) Efficacy of isoniazid prophylaxis in patients with systemic lupus erythematosus receiving long term steroid treatment. Ann Rheum Dis 61, 251-3.
17. Parsons LM, Driscoll JR, Taber HW, Salfinger M (1997) Drug resistance in tuberculosis. Infect Dis Clin North Am 11, 905-28.
18. Telenti A (1997) Genetics of drug resistance in tuberculosis. Clin Chest Med 18, 55-64.
19. Nolan CM, Aitken ML, Elarth AM, Anderson KM, Miller WT (1986) Active tuberculosis after isoniazid prophylaxis of South East Asian refugees. Am Rev Respir Dis 133, 431-6.
20. Chaturvedi V, Singal V, Marwaha V, et al. (2004) No case of tuberculosis with low dose infliximab without loading schedule in ankylosing spondylitis: A one year open label study of toxicity and efficacy in 108 patients. Abstract Book APLAR 2004. Asia Pacific League of Associations for Rheumatology Congress, Jeju, Korea, 11-15 September 2004. Abstract No 15, p.14.